Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Parainfluenza Virus 3, Human”

19 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 19 results

Not applicableStudy completedNCT01302418
What this trial is testing

Collection and Testing of Respiratory Samples

Who this might be right for
QIAGEN ResPlex II Advanced PanelInfluenza ARespiratory Syncytial Virus Infections+15 more
QIAGEN Gaithersburg, Inc 272
Early research (Phase 1)Study completedNCT01021397
What this trial is testing

Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children

Who this might be right for
Paramyxoviridae InfectionsVirus Diseases
National Institute of Allergy and Infectious Diseases (NIAID) 12
Not applicableLooking for participantsNCT05864118
What this trial is testing

Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses

Who this might be right for
Respiratory Tract Infections
University of Nebraska 1,000
Early research (Phase 1)Study completedNCT06850051
What this trial is testing

A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.

Who this might be right for
Healthy VolunteersInfluenza VaccinationRespiratory Syncytial Virus Vaccination+2 more
Sanofi 270
Early research (Phase 1)Study completedNCT00345670
What this trial is testing

Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children

Who this might be right for
Healthy
MedImmune LLC 120
Testing effectiveness (Phase 2)Study completedNCT00686075
What this trial is testing

Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants

Who this might be right for
Healthy
MedImmune LLC 1,338
Early research (Phase 1)Study completedNCT01254175
What this trial is testing

Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children

Who this might be right for
Parainfluenza Virus 3, Human
National Institute of Allergy and Infectious Diseases (NIAID) 28
Testing effectiveness (Phase 2)Ended earlyNCT00508651
What this trial is testing

A Phase 1/2A Study to Evaluate the Safety, Immunogenicity, and Shedding of MEDI-560 in Infants 1 to < 12 Months of Age

Who this might be right for
Healthy
MedImmune LLC 30
Early research (Phase 1)Study completedNCT06026514
What this trial is testing

Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults

Who this might be right for
SARS-CoV-2 Infection
National Institute of Allergy and Infectious Diseases (NIAID) 27
Early research (Phase 1)Study completedNCT00366782
What this trial is testing

Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults

Who this might be right for
Paramyxoviridae InfectionsVirus Diseases
National Institute of Allergy and Infectious Diseases (NIAID) 51
Not applicableStudy completedNCT00111878
What this trial is testing

Study to Evaluate MEDI-534 in Healthy Adults

Who this might be right for
Respiratory Syncytial Virus InfectionsParainfluenza Infections
MedImmune LLC 120
Early research (Phase 1)Looking for participantsNCT06546423
What this trial is testing

Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age

Who this might be right for
Human MetapneumovirusHuman Parainfluenza Virus Type 3
National Institute of Allergy and Infectious Diseases (NIAID) 25
Early research (Phase 1)Study completedNCT00493285
What this trial is testing

Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age

Who this might be right for
Respiratory Viral InfectionsRespiratory Syncytial Virus InfectionsParainfluenza Virus 3, Human
MedImmune LLC 49
Early research (Phase 1)Study completedNCT03392389
What this trial is testing

Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

Who this might be right for
Human Metapneumovirus and Human Parainfluenza Infection
ModernaTX, Inc. 124
Early research (Phase 1)Study completedNCT02564575
What this trial is testing

Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults

Who this might be right for
Hemorrhagic Fever, Ebola
National Institute of Allergy and Infectious Diseases (NIAID) 30
Early research (Phase 1)Active Not RecruitingNCT06604767
What this trial is testing

Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older

Who this might be right for
Respiratory Syncytial Virus InfectionMetapneumovirus InfectionParainfluenzae Virus Infection
Sanofi Pasteur, a Sanofi Company 390
Early research (Phase 1)Temporarily pausedNCT03462004
What this trial is testing

Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein

Who this might be right for
Ebola Virus Disease
National Institute of Allergy and Infectious Diseases (NIAID) 30
Early research (Phase 1)Study completedNCT04144348
What this trial is testing

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

Who this might be right for
Human Metapneumovirus and Human Parainfluenza Infection
ModernaTX, Inc. 51
Early research (Phase 1)Study completedNCT00308412
What this trial is testing

Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants

Who this might be right for
Paramyxoviridae InfectionsVirus Diseases
National Institute of Allergy and Infectious Diseases (NIAID) 45